Dernières nouvelles pour Liberty Media (NASDAQ:FWONK) Stock

Liberty Media

Liberty Formula One Gr

Liberty Formula One Group

Liberty Media Corp along with its subsidiaries is engaged in the media and entertainment industries in North America and the United Kingdom. The company owns interests in a high-quality portfolio of assets across the media, entertainment and sports industries. The company derives its maximum revenue from United Kingdom.

Liberty Media Corporation - Series C Liberty Formula One Common Stock

Liberty Media Corp

Baird analyst Ben Kallo maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Outperform and lowers the price target from $370 to $320.

News

Price Target

Analyst Ratings

TSLA

Baird Maintains Outperform on Tesla, Lowers Price Target to $320

Ahead of Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) first-quarter earnings, this analyst expects Google's parent to deliver on the advertising revenue and expects an "earnings surprise."
What Happened: The Chairman and Founder of Navellier &amp; Associates, Louis Navellier, spoke about Alphabet's first quarter forecast in his podcast ‘Market Buzz'.
&#8220;Well, their sales are forecasted to go up 10.7%, and earnings are forecast to grow 7%. Google does not provide any guidance whatsoever, but it has a very good earnings surprise history. I think what everybody&#8217;s going to be looking at is their advertising revenue very carefully," he said.
According to him, March's strong retail sales will help push Google's<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44909414/google-parent-alphabets-topline-can-withstand-pressure-in-uncertain-macro-scenario-compared-to-peers-analyst"> advertising revenue</a> in the said quarter. &#8220;Based on the strong retail sales we had in March, the strongest in two years, I would think Google&#8217;s advertising revenue would pick up.&#8221;
Last week, a <a href="https://www.benzinga.com/news/legal/25/04/44876356/google-scores-partial-win-in-antitrust-case-but-faces-setback-on-publisher-tools">U.S. District Judge ruled</a> that the Department of Justice won its antitrust case against Alphabet&#8217;s Google, finding the company illegally monopolized advertising technology. 
The ruling concluded that Google engaged in anticompetitive practices for over a decade by bundling its publisher ad server and ad exchange to maintain its monopoly in those open-web display ad markets.
Navellier added, &#8220;The only glitch is, of course, the Department of Justice has won a suit against them to break them up. You know, breaking up Google is kind of like a dog catching a car. I mean, what does the dog do now? They&#8217;re trying to appease the government, and I&#8217;m sure with Trump in it&#8217;s going to be a little different, but I think they&#8217;re trying to spin off Chrome, so we&#8217;ll see what happens, but Google normally beats.&#8221;
See Also: <a href="https://www.benzinga.com/25/04/44945402/wedbushs-dan-ives-raises-teslas-price-target-to-350-as-musk-promises-to-significantly-reduce-doge-time">Wedbush&#8217;s Dan Ives Raises Tesla&#8217;s Price Target To $350 As Elon Musk Promises To &#8216;Significantly&#8217; Reduce DOGE Time</a>
Why It Matters: The company will be reporting its first-quarter earnings on April 24. Alphabet's technical charts indicated that its premarket price of $157.66 per share at the time of the publication was above its short-term simple daily moving averages but below its long-term averages.
The relative strength index of 43.78 was neutral, whereas its MACD line was at negative 4.04. However, its 12-day exponential moving average was above the 26-day EMA, with a positive histogram of 0.47, indicating a bullish trend.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071926/GOOG-Tech-1024x576.png" alt="" class="wp-image-883854" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071926/GOOG-Tech-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071926/GOOG-Tech-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071926/GOOG-Tech-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071926/GOOG-Tech-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071926/GOOG-Tech.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The stock was up 2.44% in premarket, but it has fallen by 19.27% on a year-to-date basis. It was 3.76% lower over the year.
Benzinga Edge Stock Rankings shows that GOOG had a weaker price trend over the short, medium, and long term. Its momentum ranking was moderate at the 48.43 percentile, whereas its value ranking was also moderate; the details of other metrics are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>. 
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/report/TSLA"><img loading="lazy" decoding="async" width="1024" height="146" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071909/GOOG-EDGE-1024x146.png" alt="" class="wp-image-883853" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071909/GOOG-EDGE-1024x146.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071909/GOOG-EDGE-300x43.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071909/GOOG-EDGE-768x110.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23071909/GOOG-EDGE.png 1206w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Wednesday. The SPY was up 2.50% to $540.42, while the QQQ advanced 3.20% to $457.91, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/04/44945107/bearish-charts-and-upbeat-q1-estimates-heres-how-chipotle-stock-is-doing-after-recent-pric">Chipotle Stock Faces Bearish Charts Despite Upbeat Q1 Estimates And Price Target Revisions</a></li>
</ul>
Image Via Shutterstock

Analyst Color

Earnings

Earnings Beats

Earnings Misses

Equities

Market Summary

Broad U.S. Equity ETFs

Guidance

Futures

Technicals

Markets

Trading Ideas

ETFs

General

GOOG

GOOGL

NFLX

'Google Normally Beats,' Says Analyst Expecting Sundar Pichai-Led Company's Ad Revenue To 'Pick Up' In Q1: Here's What Alphabet's Chart Shows Ahead Of Earnings

William Blair analyst Brian Drab upgrades Valmont Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMI#NYSE">VMI</a>) from Market Perform to Outperform.

Upgrades

William Blair Upgrades Valmont Industries to Outperform

SAN RAFAEL, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has named Bionic Prosthetics &amp; Orthotics Group LLC ("Bionic P&amp;O"), a leading national provider of prosthetic and orthotic solutions, as a non-exclusive Ekso Indego&#xAE; Personal device distributor.

EKSO

Ekso Bionics Holdings Selects Bionic Prosthetics & Orthotics Group As Non-Exclusive Ekso Indego Personal Device Distributor

Baird analyst Michael Halloran maintains Pentair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) with a Outperform and lowers the price target from $114 to $107.

Baird Maintains Outperform on Pentair, Lowers Price Target to $107

Newly allowed patent extends Wearable Devices' innovative gesture technology into the domain of voice control
YOKNEAM ILLIT, ISRAEL, April 23, 2025 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (the "Company" or "Wearable Devices") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDS#NASDAQ">WLDS</a>, WLDSW))), a technology growth company specializing in artificial intelligence ("AI")-powered touchless sensing wearables, today announced that the United States Patent and Trademark Office has allowed its patent titled "Gesture and Voice-Controlled Interface Device."
This patent represents a significant advancement in the Company's strategic intellectual property ("IP") portfolio, strengthening global protection for its core innovations in wearable bio-potential sensors. The Company's IP strategy includes patent families designed to protect a wide spectrum of future applications, ensuring agility in response to emerging global market needs.

WLDS

Wearable Devices Granted U.S. Patent For Gesture And Voice-Controlled Interface Device

ONMD

OneMedNet And Protege Partner To Enable Real-Time Access, Multimodal Patient Data For AI Developers And Researchers

Baird analyst Mircea Dobre maintains Herc Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRI#NYSE">HRI</a>) with a Neutral and lowers the price target from $129 to $110.

Baird Maintains Neutral on Herc Holdings, Lowers Price Target to $110

UBS analyst Peter Grom initiates coverage on Simply Good Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMPL#NASDAQ">SMPL</a>) with a Neutral rating and announces Price Target of $41.

Initiation

SMPL

UBS Initiates Coverage On Simply Good Foods with Neutral Rating, Announces Price Target of $41

Norfolk Southern Affirms FY2025 Sales Guidance of $12.49B vs $12.37B Est

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLT#NASDAQ">RZLT</a>) ("Rezolute" or the "Company"), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the pricing of an underwritten offering, priced at-the-market under Nasdaq rules, of an aggregate of 20,786,923 shares of its common stock at an offering price of $3.25 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 6,905,385 shares of common stock at an offering price of $3.2490 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. Gross proceeds from the underwritten offering before deducting underwriting discounts and commissions and other offering expenses are expected to be approximately $90 million. Rezolute has also granted the underwriters a 30-day option to purchase up to an additional 4,153,846 shares of common stock at the offering price, less underwriting discounts and commissions.
All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Rezolute. The closing of the offering is expected to occur on or about April 24, 2025, subject to the satisfaction of customary closing conditions.
The deal includes participation from new and existing investors, including Federated Hermes Kaufmann Funds, Blackstone Multi-Asset Investing, Great Point Partners, LLC, Marshall Wace, Woodline Partners LP, Nantahala Capital, Squadron Capital Management and select mutual funds.

Offerings

RZLT

Rezolute Announces Pricing Of Offering Of $90M At $3.35 Per Share Of Common Stock And Pre-Funded Warrants

Macro Economic Events

Econ #s

Economics

Reported Earlier: Building Permits (MoM) For March 0.5% Vs 1.6% Est.; -1.0% Prior

Baird analyst Eric Coldwell maintains Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) with a Neutral and lowers the price target from $340 to $313.

MEDP

Baird Maintains Neutral on Medpace Hldgs, Lowers Price Target to $313

Reported Earlier: USA Building Permits For March 1.467M Vs 1.482M Est.; 1.459M Prior

BYD Co., Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) is pivoting its European strategy as the Chinese EV manufacturer looks to expand into the market.
What Happened: Failing to hire executives with an understanding of the European market, as well as a small dealer network, were some of the ‘strategic missteps' BYD took as it entered into Europe, sources told Reuters on Wednesday.
BYD targeted at least 5% of the European EV Market prior to beginning production at its facility in Hungary, the report says, citing former BYD European Chief Michael Shu. However, the company fell way below expectations, selling over 57,000 vehicles in 2024 with a 2.8% market share.
BYD had announced that Plug-In Hybrids would play a crucial role in its European strategy. That decision came after advice from the company's European special adviser, Alfredo Altavilla — a key figure in the rejig who convinced the brand that EV penetration in many European markets still lags behind ICE and Hybrids, the report suggests.
"It is necessary to educate customers in the green transition.&#8221; Altavilla shared in the report. BYD has since hired various executives from rival companies like Stellantis NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) as well as appointed executive VP Stella Li in charge of Europe, the report says.
The company's sales in Europe have since experienced a surge, having sold over 37,000 units in the region — including the United Kingdom — in Q1 2025. The company had sold just over 8,500 units last year, around the same time.
Why It Matters: BYD has recently made headway into Japan as the company targets the local minicar market with <a href="https://www.benzinga.com/markets/emerging-markets/25/04/44904375/tesla-rival-byd-targets-japans-minicar-market-with-for-new-affordable-ev">an affordable EV</a>. The company had also disrupted the Chinese domestic market by introducing its God's Eye driver assistance system even in affordable models.
BYD had recently unveiled<a href="https://www.benzinga.com/trading-ideas/movers/25/04/44630091/teslas-ev-crown-at-risk-as-byd-closes-in-with-breakthrough-charging-tech"> new charging tech</a>, which was capable of providing over 250 miles of range in just over 5 minutes of charging. BYD is now the world's largest battery EV manufacturer with over 15.7% of the global market share.
Elsewhere, other Chinese manufacturers are also making their way to the European market. However, it could prove to be difficult as Nio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) recently announced a delay to the launch of its <a href="https://www.benzinga.com/25/04/44915240/tesla-rival-nio-delays-the-european-launch-of-firefly-ev-report">Firefly EV in Europe</a>.&nbsp;
Price Action: BYDDF currently trades for $49.13, according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro data</a>.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44945220/chinas-geely-announces-it-will-share-battery-safety-patents-safety-lab-with-the-auto-industry">China&#8217;s Geely To Share Battery Safety Patents, Unveils World&#8217;s Largest EV Safety Lab At Shanghai Auto Show</a></li>
</ul>
Photo by Cobalt S-Elino via Shutterstock

Tech

BYDDF

BYDDY

STLA

BYD Resets European EV Strategy After Missing 5% Market Goal Amid Poor Hiring, Weak Dealer Network: Report

<ul>
<li>Building on operational momentum across the network- &gt;$150M of year-over-year productivity savings in 2025</li>
<li>3% revenue growth</li>
<li>150 bps of year-over-year Operating Ratio improvement</li>
<li>Focused on narrowing the OR gap to peers</li>
<li>Improving cash flow and shareholder returns-Capex expected to be ~$2.2B in 2025 and &nbsp;Continued execution of share repurchase plan</li>
</ul>

Norfolk Southern Reiterates Full-Year 2025 Guidance While Recognizing Macro-Economic Uncertainty

Baird analyst David Rescott maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Outperform and lowers the price target from $600 to $575.

ISRG

Baird Maintains Outperform on Intuitive Surgical, Lowers Price Target to $575

On April 23, 2025, Novavax, Inc. (the "Company") issued the following statement:
&nbsp;
We believe that our Biologics License Application ("BLA") is approvable based on conversations with U.S. Food and Drug Administration ("FDA"), as of our Prescription Drug User Fee Act date on April 1 and through today.
&nbsp;
We have recently received formal communication from the FDA in the form of an information request for a post marketing commitment ("PMC") to generate additional clinical data. We look forward to engaging with the FDA expeditiously to address the PMC request and move to approval as soon as possible.&nbsp;&nbsp;

NVAX

Novavax Believes Its Biologics License Application Is Approvable Based On Conversations With FDA As Of PDUFA Date On Apr. 1 And Through Today

Key update provides operators invaluable control and reliability in environments where GNSS/GPS signals are compromised, jammed, or entirely unavailable&nbsp;
WICHITA, Kan., April 23, 2025 (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#NYSE">UAVS</a>) ("AgEagle" or the "Company"), a leading provider of best-in-class unmanned aerial systems (UAS) and sensors for military, public safety, and commercial use, announces the launch of its eBee VISION next generation application software featuring a variety of critical updates. Of particular note, is the capability for manual position updates with map referencing to provide precise navigation even in GNSS-denied areas where satellite signals are unavailable or unreliable due to various factors.&nbsp;
AgEagle CEO Bill Irby commented, "Of the many new features provided in our latest software update, overcoming GNSS-denied shortfalls marks a significant leap forward in drone operations especially for defense personnel, public safety agencies and industrial teams working in high-stakes, GNSS-denied environments. Whether operating in dense urban centers, near critical installations, or in contested zones with active signal interference, our global eBee VISION customers can now maintain full navigational command of their drone using only the camera and map-based interface. This feature directly addresses a core challenge faced by tactical and industrial drone operators in today's complex mission environments. Our technical team will continue to work relentlessly on refinements and ongoing advancements to ensure AgEagle remains at the forefront of UAV innovation."
Key Advantages of Manual Position Control Without GNSS:
<ul>
<li>Operational Continuity in Denied or Degraded Environments: Enables uninterrupted drone navigation when GPS is jammed, spoofed, or blocked—common scenarios in tactical defense and critical infrastructure inspections.</li>
<li>Enhanced Mission Flexibility: Supports real-time adjustments to the drone's perceived position using visual confirmation and mapping, empowering operators to adapt quickly in evolving environments.</li>
<li>Situational Resilience: Increases overall reliability of drone-based intelligence, surveillance, and reconnaissance (ISR) operations in hostile or unpredictable conditions.</li>
</ul>

Retail Sales

UAVS

Ageagle Aerial Systems Launches Its eBee VISION Next Generation Application Software Featuring A Variety of Critical Updates

Calidi Biotherapeutics Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#NYSE">CLDI</a>) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer ("CEO"), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi ("Board"), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board.

Management

CLDI

Calidi Biotherapeutics  Announces The Succession Of Its CEO, Allan Camaisa, To Eric Poma, Who Was Appointed As CEO And Member Of The Board Of Directors, Effective April 22, 2025

Press Releases

Liberty Media Corporation Announces Plan to Split Off Liberty Live Group

Greg Maffei to Step Down as Liberty Media CEO at Year-End in Conjunction with Transactions to Simplify Corporate Structure

Liberty Media Appoints Chase Carey to Board of Directors

Liberty Media Names Robert R. Bennett as Vice Chairman of Board of Directors

Liberty Media Statement on European Commission Decision to Open Phase II Investigation of Proposed Acquisition of MotoGP™

Liberty Media Names Derek Chang as President & Chief Executive Officer

Liberty Media Corporation Announces Fourth Quarter Earnings Release and Conference Call

Liberty Media Corporation Announces 2025 Virtual Annual Meeting of Stockholders

Liberty Media Corporation Reports Fourth Quarter and Year End 2024 Financial Results

Liberty Media Corporation Announces First Quarter Earnings Release and Conference Call

FWONA

FWONK

LLYVA

LLYVK

AMC Entertainment Holdings, Inc. Class A Common Stock

AMC Entertainment Hldgs

Atlanta Braves Holdings, Inc. - Series A Common Stock

Atlanta Braves Holdings

Atlanta Braves Holdings, Inc. - Series C Common Stock

Cinemark Holdings Inc Cinemark Holdings, Inc. Common Stock

Cinemark Holdings

Walt Disney

Liberty Media Corporation - Series A Liberty Formula One Common Stock

Ordinary Shares (New Liberty Formula One) Series A

Ordinary Shares (New Liberty Formula One) Series C

iQIYI

Lions Gate Entertainment Corporation Class A Voting Shares

Lions Gate Entertainment Corporation Class B Non-Voting Shares

Lionsgate Studios

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live

Ordinary Shares (New Liberty Live) Series A

Liberty Media Corporation - Series C Liberty Live Common Stock

Ordinary Shares (New Liberty Live) Series C

Live Nation Entertainment, Inc. Common Stock

Live Nation Entertainment

Manchester United Ltd. Class A Ordinary Shares

Manchester United

Marcus

Madison Square Garden Entertainment Corp. Class A Common Stock

Madison Square Garden

Madison Square Garden Sports Corp. Class A Common Stock (New)

Netflix

Roku

Reservoir Media

Sphere Entertainment Co. Class A Common Stock

Sphere Entertainment

TKO Group Holdings, Inc. Class A Common Stock

TKO Group Holdings

Tencent Music Entertainment Group American Depositary Shares, each representing two Class A Ordinary Shares

Comments

Liberty Media

Actualités

Dernières nouvelles pour Liberty Media (NASDAQ:FWONK) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL